alvotech

Q2 2024 Earnings

AUGUST 16, 2024

Disclaimer

This presentation ("Presentation") does not contain or constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Alvotech (the "Company") to any person in the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Any trademarks, servicemarks, trade names and copyrights of the Company and other companies contained in this Presentation are the property of their respective owners.

Forward-Looking Statements

This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or future financial or operating performance of the Company and may include, for example, the Company's expectations regarding capitalization through equity or debt financing, Alvotech's ability to maintain listing requirements, future growth, results of operations, performance, projections of future revenue and cash runway, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, the re-inspection of the Company's manufacturing site by the FDA, the expectation that the FDA's facility inspection in March 2023 will also serve as the pre-license inspection for AVT04, potential approval, including for AVT02 and AVT04, by the FDA and other regulatory agencies, commercial launch of the Company's products and product candidates, including AVT02 in the U.S., the timing and progress of the announcement of clinical study results, the commencement of patient studies, regulatory approvals and market launches, the Company's partnerships, including with Teva and information about the market opportunity of the Company's pipeline products. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond the Company's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the Company or others following the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II and Alvotech; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (5) the Company's estimates of expenses and profitability; (6) the Company's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (8) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (9) the ability of the Company or its partners to enroll and retain patients in clinical studies; (10) the ability of the Company or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of the Company's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) the Company's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of the Company's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) the Company's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) the Company's ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding the Company's products and product candidates; (17) the potential impact of the ongoing COVID-19 pandemic on the FDA's review timelines, including its ability to complete timely inspection of manufacturing sites; and (18) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Company's business, financial position, strategy and anticipated milestones; and (19) other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in documents that the Company may from time to time file or furnish with the SEC. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company's industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk. Nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this Presentation.

Non-IFRS Financial Measures

This Presentation may include projections of certain financial measures not presented in accordance with International Financial Reporting Standards ("IFRS") including, but not limited to, Adjusted EBITDA and certain ratios and other metrics derived therefrom. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing the Company's financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. You should be aware that the Company's presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable IFRS financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable IFRS measures is included and no reconciliation of the forward-looking non-IFRS financial measures is included. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Agenda

1 OVERVIEW

2 COMMERCIAL UPDATE

3 FINANCIAL UPDATE

4 Q&A

ROBERT WESSMAN
Chairman and Chief Executive Officer

ANIL OKAY
Chief Commercial Officer

JOEL MORALES
Chief Financial Officer

MING LI
Chief Strategy Officer

BENEDIKT STEFÁNSSON
VP of IR and Global Communication



alvotech

Robert Wessman

Chairman and
Chief Executive Officer

Strong Start to 2024

Key Highlights 1H-2024

1H **and** Q2 delivered positive adjusted EBITDA for the first time in company's history

→ 84% of total revenue in the period from 2nd quarter

Results driven by;

→ Global launches of AVT04, biosimilar to Stelara®

→ U.S. launch of AVT02, biosimilar to Humira®

→ Advancement of portfolio and pipeline

→ New commercial partnership arrangements

1H 2024 Performance

Total Revenues ↑

$235.6mn

vs. to $20.3mn in 1H-23

Product Revenues ↑

$65.9mn

vs. $22.7mn in 1H-23

Adjusted EBITDA ↑

$63.5mn

vs. ($146.7mn) loss in 1H-23

Milestone Revenues ↑

$169.7mn

vs. ($2.5mn) in 1H-23

Continued Progress and Execution (2024)



Continued Evolution of Alvotech

PORTFOLIO GROWTH AND DIVERSIFICATION

47 Unique launches achieved across 2 biosimilars

Expect at least 70 unique launches before end of ’25 from AVT04 or AVT02

3 BLA submissions expected in ’24

Certain launches from new molecules expected before end of ’25

PLATFORM LEVERAGE

No increase in headcount ’24 vs. ’23 despite;

- >3x increase in manufacturing output
- Record level of pipeline activity

alvotech

Anil Okay

Chief Commercial Officer



Commercialization of Humira Biosimilar in the U.S.

PRIVATE LABEL

- Commercialization agreement with Quallent, part of the Cigna network
- adalimumab-ryvk is interchangeable to the reference product
- Product is available at $0 out of pocket cost through Accredo specialty pharmacy
- ~20% of CIGNA Humira book converted to biosimilars in ~5 weeks[1]
- Economics change to a profit share between Teva and Alvotech

SIMLANDI FORMULARY

Simlandi (adalimumab-ryvk) Injection

- SIMLANDI® is interchangeable to the reference product
- Soft launch in May targeted GPO/Hospital business
- As of July, SIMLANDI® is now listed as preferred on Express Scripts (part of CIGNA), CarelonRx, Navitus, Blue Cross Blue Shield of Mass. and La.
- Expect gradual ramp in prescriptions in 2024 with acceleration into 2025
- Economics remain the same as a 40/60 revenue share (Alvotech/Teva)

- **~1.3 million units of binding purchase orders for 2024 across both channels(US ONLY)**
- **>80% of orders expected to be delivered in 2H, more weighted to Q4**

(1)Source; Cigna Group 2nd quarter earnings call held August 01, 2024

AVT04 in the first wave in key markets

	CANADA	JAPAN	Europe	U.S.
Launch	Jamteki™ ustekinumab injection **Launched March 2024**	ウステキヌマブBS皮下注シリンジ「F」 **Launched May 2024**	Uzpruvo® solution for injection ustekinumab **Launched July 2024**	Selarsdi™ (ustekinumab-aekn) **Expected February 2025**
Partner	JAMP PHARMA GROUP	Fuji Pharma Co., Ltd.	STADA	teva
Addressable Market	**$0.7Bn[1]**	**$0.4Bn[1]**	**$3.1Bn[1]**	**$7Bn[2]**
Current Marketing Companies[3]	**Alvotech, Amgen**	**Alvotech**	**Alvotech, Sandoz**	**NA**
Volume Trends[1] CAGR% ('19-'23)	**21%**	**21%**	**34%**	**19%**

(1) IQVIA
(2)JnJ financial reports (MAT)
(3)Based on public information

Pipeline Update

AVT06

EYLEA® (aflibercept) Injection 2 mg

- Biosimilar candidate to Eylea®
- $10 Bn[1] leading biologic for retinal diseases
- Developing for both vial and pre-filled syringe
- Expect to seek interchangeability designation
- Partnership with Advanz Pharma for EU finalized in June ‘24
- Marketing application accepted by EMA with decision expected Q3, 2025
- Further announcements expected for other markets in ‘24

AVT29

EYLEA® HD (aflibercept) Injection 8 mg

- Biosimilar candidate to Eylea® HD
- Partnership with Advanz Pharma for EU finalized in June ’24
- Other partners include Teva (US)
- Formulation and process have been developed and program currently in scale-up phase

AVT05

Simponi® golimumab

Simponi ARIA® golimumab for infusion

- Targeting both Simponi® (pharmacy benefit) and Simponi Aria® (medical benefit)
- Established anti-TNF with SP2/0 technology barrier
- Only one other company has completed a clinical trial utilizing a biosimilar candidate
- Alvotech is the only known company to have biosimilars for Humira®, Stelara® and an advanced program for Simponi® in major markets
- Expect filing in 2024

(1) Regeneron financial reports (2023)

Pipeline Update (continued)

alvotech

AVT03

prolia® (denosumab) injection
XGEVA® (denosumab)

- Biosimilar candidate to Prolia® and Xgeva®
- High potential in women health
- Both a Medical benefit and pharmacy benefit product in the U.S.
- Partnership with Dr. Reddy's Laboratories finalized in May '24 for the U.S. and European market[1]
- Partnership with STADA in Europe finalized in June '24[1]
- Expect filing in 2024

AVT23

Xolair® omalizumab

- Biosimilar candidate to Xolair®
- Licensed from Kashiv BioSciences
- Growing market and limited competition
- Partnered with Advanz; agreement covers 27 countries of the European union, the UK, Australia, Canada and New Zealand
- Successful Phase 1 study
- Completion of enrollment for Phase III Clinical trial announced in July 2024

AVT16

Entyvio® vedolizumab

- Biosimilar candidate to Entyvio®
- Steadily growing biologic leading in IBD
- $5.6 Bn1 global market and expected limited competition
- Clinical phase initiated; pilot safety study complete
- 1st dosing in patient trial expected in September 2024

AVT33

KEYTRUDA® (pembrolizumab)

- Biosimilar candidate to Keytruda®
- Rapidly growing $27 Bn[1] oncology biologic
- At-scale production planed for 2025; initiating tech transfer
- Concurrently, finalizing clinical design
- First subject dosing in clinical trial expected in late 2025
- Partnership for AVT33 remains in active discussion with multiple parties

(1)semi-exclusive in EU markets

alvotech

Joel Morales

Chief Financial Officer

Closing of Private Financing Leads to More Simplified Capital Structure

alvotech

- $965m Gross Debt
- SOFR based facility vs. previous fixed rate debt
- Removes short dated maturities
- Favorable call features
- All convertible bonds converted/redeemed
- Provides substantial cash to the balance sheet
- Remaining debt includes new term loan facility, mortgage, and equipment financing

1H 2024 Financial Highlights

alvotech

OPERATING PERFORMANCE

- Total revenue of $236 million, over 10x increase versus prior year.
- $170 million of milestone revenue, primarily due to advancement of the pipeline and new product launches.
- $66 million of product revenues driven by Humira biosimilar launch in US and Stelara biosimilar launch in ex-US markets.
- Adjusted EBITDA of $64 million, versus negative ($147) million in prior year.

CASH AND LIQUIDITY

- Finalized financing facilities providing net proceeds of $142 million.
- $11 million of cash on hand as of June 30.
- Giving effect to the financing, $178 million of proforma cash on hand as of June 30, including $25 million of restricted cash.
- Sufficient cash runway to free cash flow positive.

SHARES OUTSTANDING

- 279.4 million shares outstanding as of June 30.
- Includes 39.6 million of earnout shares, of which 19.2 million not currently vested.
- Giving effect to the conversion of Convertible Bonds on July 1st, 301.5 million proforma shares outstanding as of June 30.
- Excludes shares to be issued for certain programs and arrangements that are not yet settled as of June 30.

Key Drivers of 2024 Outlook

REVENUES | **$400-500m**

ADJUSTED EBITDA | **$100-150m**

SIMLANDI® and adalimumab-rykv

First interchangeable, high concentration biosimilar to Humira in the U.S.

Simlandi (adalimumab-ryvk) Injection

PIPELINE ADVANCEMENT

Major market filings for at least 3 additional biosimilar candidates driving additional milestone revenue and further advancement of longer-term pipeline

JAMTEKI®

First biosimilar to Stelara®, available in the Canadian Market

Jamteki™ ustekinumab injection

SELARSDI® SUPPLY INITIATION

Launch expected February ’25 in the U.S. with potential supply in Q4 2024

Selarsdi (ustekinumab-aekn)

AVT04 in Japan (USTEKINUMAB)

First biosimilar to Stelara®, available in the Japanese Market

ウステキヌマブBS皮下注シリンジ[F]

UZPRUVO®

Launches of biosimilar to Stelara® in Europe initiated in July 2024

Uzpruvo® solution for injection ustekinumab

PARTNERSHIP TRANSACTIONS

Inclusive of but not limited to previously announced deals with DRL for AVT03 in the U.S. and Europe



alvotech

Appendix

Reported to Adjusted Reconciliation

$ millions	H1 2024 Reported	H1 2024 Adjustment Entries	H1 2024 Adjusted	H1 2023 Reported	H1 2023 Adjustment Entries	H1 2023 Adjusted
Product Revenue	65.9	-	65.9	22.7	-	22.7
License and Other Revenue	169.7	0.1	169.7	(2.5)	0.0	(2.4)
Other Income	0.1	(0.1)	-	0.0	(0.0)	-
Cost of Product Revenue	(65.2)	0.5	(64.7)	(67.9)	2.1	(65.8)
R&D	(97.5)	0.9	(96.6)	(99.6)	19.8	(79.8)
G&A	(29.6)	3.9	(25.6)	(41.9)	9.7	(32.2)
Operating Profit (Loss)	**43.4**	**5.3**	**48.7**	**(189.1)**	**31.7**	**(157.4)**
Share of Net Loss of JV	-	-	-	(2.7)	-	(2.7)
Impairment loss on inv. in JV	(1.8)	1.8	-	-	-	-
Finance Income	80.8	(79.1)	1.7	122.5	(119.5)	3.0
Finance Costs	(277.4)	193.5	(83.9)	(64.3)	5.9	(58.4)
Exchange Rate Diffrences	7.7	(7.7)	-	(3.1)	3.1	-
Loss Before Taxes	**(147.2)**	**113.8**	**(33.4)**	**(136.7)**	**(78.9)**	**(215.6)**
Income Tax Benefit	(5.1)	0.5	(4.6)	49.9	(4.5)	45.3
Loss For The Period	**(152.4)**	**114.3**	**(38.1)**	**(86.9)**	**(83.4)**	**(170.3)**
Loss Per Share (in $)	**(0.60)**		**(0.15)**	**(0.39)**		**(0.76)**
EBITDA:						
Operating Profit (Loss)	**43.4**	**5.3**	**48.7**	**(189.1)**	**31.7**	**(157.4)**
D&A	14.7	-	14.7	10.9	-	10.9
EBITDA	**58.2**	**5.3**	**63.5**	**(178.2)**	**31.7**	**(146.5)**

H1 2024 Adjustment Entries

Cost of Product Revenue	– $0.5m charge related to long-term incentive plan
R&D	– $1.4m charge related to long-term incentive plan (non-cash) – ($0.6m) IP litigation costs attributable to programs - reclassified from G&A
G&A	– $3.3m charge related to long-term incentive plan (non-cash) – $0.6m IP litigation costs attributable to programs - reclassified to R&D
Impairment loss on inv. in JV	– $1.8m from sales of China JV
Finance Income	– ($79.1m) fair value adjustment on derivatives (non-cash)
Finance Costs	– $130.4m fair value adjustment on derivatives (non-cash) – $63.1m loss on remeasurement of bonds (non-cash)
Exchange Rate Differences	– ($7.7m) impact of exchange rate fluctuations (non-cash)
Income Tax	– $0.5m tax impact of discrete adj. in jurisdictions where tax benefits are available

H1 2023 Adjustment Entries

Cost of Product Revenue	– $1.8m charge related to long-term incentive plan (non-cash) – $0.3m impairment and loss on sale of fixed asset
R&D	– $18.5m of one-time, Biosana accounts receivables reserve pertaining to the termination of AVT-23 (non-cash) – $2.6m charge related to long-term incentive plan (non-cash) – ($1.3m) IP litigation costs attributable to programs - reclassified from G&A
G&A	– $0.9m of one-time costs in connection with the Iceland main board listing – $1.3m IP litigation costs attributable to programs - reclassified to R&D – $7.5m charge related to long-term incentive plan (non-cash)
Finance Income	– ($119.5m) fair value adjustment on derivatives (non-cash)
Finance Cost	– $5.9m fair value adjustment on derivatives (non-cash)
Exchange Rate Differences	– $3.1m impact of exchange rate fluctuations (non-cash)
Income Tax	– ($4.5m) tax impact of discrete adjustments in jurisdictions where tax benefits are available

Capital Structure as of June 30, 2024

Common Shares Outstanding as of 30 June 2024 (in millions)	**279.4**
Issued shares (from convertible bonds)[1]	22.1
Pro Forma Common Shares Outstanding as of 1 July 2024 (in millions)	**301.5**
Potential future dilution:	
OACB Private Warrants [2]	*0.7*
OACB Public Warrants	*5.3*
RSUs	*2.7*
Senior Bond Warrants	*0.2*
TOTAL POTENTIAL FUTURE DILUTION	*8.9*

[1] On 26 June 2024, the Company announced that all holders of the Tranche A and some holders of the Tranche B of the 2022 Convertible Bonds exercised their right to conversion into ordinary shares at the fixed conversion price of $10.00 per share on the last scheduled conversion date prior to maturity, which is 1 July 2024. Based on the current exchange rate, a total of approximately 22.1 million new shares were issued on 1 July 2024, corresponding to approximately $221.1 million of aggregate value of these bonds with accrued interest.

[2] Using the Company's average stock price of $13.52 and calculated in accordance with the Warrant Agreement dated September 21, 2020.

alvotech

Thank you

alvotech

Additional information

investors.alvotech.com

alvotech.com

alvotech.is

alvotech.ir@alvotech.com